CA2402299C - Serum free cultivation of primate embryonic stem cells - Google Patents
Serum free cultivation of primate embryonic stem cells Download PDFInfo
- Publication number
- CA2402299C CA2402299C CA2402299A CA2402299A CA2402299C CA 2402299 C CA2402299 C CA 2402299C CA 2402299 A CA2402299 A CA 2402299A CA 2402299 A CA2402299 A CA 2402299A CA 2402299 C CA2402299 C CA 2402299C
- Authority
- CA
- Canada
- Prior art keywords
- culture
- stem cells
- embryonic stem
- serum
- growth factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
Abstract
Disclosed herein are methods for culturing primate embryonic stem cells. These cells are cultured on a prolonged and stable basis in the presence of exogenously supplied fibroblast grown factor and in the absence of animal serum. Preferably there is also a fibroblast feeder layer. Also disclosed is a culture media containing fibroblast feeder layer and the fibroblast growth factor.
Description
SERUM FREE CULTIVATION OF PRIMATE EMBRYONIC STEM CELLS
BACKGROUND OF THE INVENTION
The present invention relates to methods for culturing primate embryonic stem cell cultures and culture media useful therewith.
Primate (e.g. monkey and human) pluripotent embryonic stem cells have been derived from preimplantation embryos. See U.S. patent 5,843,780 and J. Thomson 282 Science 1145-1147 (1998).
Notwithstanding prolonged culture, these cells stably maintain a developmental potential to form advanced derivatives of all three embryonic germ layers.
Primate (particularly human) ES cell lines have widespread utility in connection with human developmental biology, drug discovery, drug testing, and transplantation medicine. For example, current knowledge of the post-implantation human embryo is largely based on a limited number of static histological sections.
Because of ethical considerations the underlying mechanisms that control the developmental decisions of the early human embryo remain essentially unexplored.
Although the mouse is the mainstay of experimental mammalian developmental biology, and although many of the fundamental mechanisms that control development are conserved between mice and humans, there are significant differences between early mouse and human development.
Primate/human ES cells should therefore provide important new insights into their differentiation and function.
BACKGROUND OF THE INVENTION
The present invention relates to methods for culturing primate embryonic stem cell cultures and culture media useful therewith.
Primate (e.g. monkey and human) pluripotent embryonic stem cells have been derived from preimplantation embryos. See U.S. patent 5,843,780 and J. Thomson 282 Science 1145-1147 (1998).
Notwithstanding prolonged culture, these cells stably maintain a developmental potential to form advanced derivatives of all three embryonic germ layers.
Primate (particularly human) ES cell lines have widespread utility in connection with human developmental biology, drug discovery, drug testing, and transplantation medicine. For example, current knowledge of the post-implantation human embryo is largely based on a limited number of static histological sections.
Because of ethical considerations the underlying mechanisms that control the developmental decisions of the early human embryo remain essentially unexplored.
Although the mouse is the mainstay of experimental mammalian developmental biology, and although many of the fundamental mechanisms that control development are conserved between mice and humans, there are significant differences between early mouse and human development.
Primate/human ES cells should therefore provide important new insights into their differentiation and function.
Differentiated derivatives of primate ES cells could be used to identify gene targets for new drugs, used to test toxicity or teratogenicy of new compounds, and used for transplantation to replace cell populations in disease. Potential conditions that might be treated by the transplantation of ES cell-derived cells include Parkinson's disease, cardiac infarcts, juvenile-onset diabetes mellitus, and leukemia. See e.g. J. Rossant et al. 17 Nature Biotechnology 23-4 (1999) and J. Gearhart, 282 Science 1061-2 (1998).
Long term proliferative capacity, developmental potential after prolonged culture, and karyotypic stability are key features with respect to the utility of primate embryonic stem cell cultures. Cultures of such cells (especially on fibroblast feeder layers) have typically been supplemented with animal serum (especially fetal bovine serum) to permit the desired proliferation during such culturing.
For example, in U.S. patents 5,453,357, 5,670,372 and 5,690,296 various culture conditions were described, including some using a type of basic fibroblast growth factor together with animal serum. Unfortunately, serum tends to have variable properties from batch to batch, thus affecting culture characteristics.
In WO 98/30679 there was a discussion of providing a serum-free supplement in replacement for animal serum to support the growth of certain embryonic stem cells in culture. The serum replacement included albumins or albumin substitutes, one or more amino acids, one or more vitamins, one or more transferrins or transferrin substitutes, one or more antioxidants, one or more insulins or insulin substitutes, one or more collagen precursors, and one or more trace elements. It was noted that this replacement could be further supplemented with leukemia inhibitory factor, steel factor, or ciliary neurotrophic factor. Unfortunately, in the context of primate embryonic stem cell cultures (especially those grown on fibroblast feeder layers), these culture media did not prove satisfactory.
In the context of nutrient serum culture media (e.g.
fetal bovine serum), WO 99/20741 discusses the benefit of use of various growth factors such as bFGF in culturing primate stem cells. However, culture media without nutrient serum is not described.
In U.S. patent 5,405,772 growth medium for hematopoietic cells and bone marrow stromal cells are described. There is a suggestion to use fibroblast growth factor in a serum-deprived media for this purpose.
However, conditions for growth primate of embryonic stem cells are not described.
It can therefore be seen that a need still exists for techniques to stably culture primate embryonic stem cells without the requirement for use of animal serum.
BRIEF SUMMARY OF THE INVENTION
In one aspect the invention provides a method of culturing primate embryonic stem cells. One cultures the stem cells in a culture essentially free of mammalian fetal serum (preferably also essentially free of any animal serum) and in the presence of fibroblast growth factor that is supplied from a source other than just a fibroblast feeder layer. In a preferred form the culture also has a fibroblast feeder layer.
Fibroblast growth factors are essential molecules for mammalian development. There are currently nine known fibroblast growth factor ligands and four signaling fibroblast growth factor receptors therefor (and their spliced variants). See generally D. Ornitz et al., 25 J.
Biol. Chem. 15292-7 (1996); U.S. patent 5,453,357.
Slight variations in these factors are expected to exist between species, and thus the term fibroblast growth factor is not species limited. However, I prefer to use human fibroblast growth factors, more preferably human basic fibroblast growth factor produced from a recombinant gene. This compound is readily available in quantity from Gibco BRL-Life Technologies and others.
It should be noted that for purposes of this patent the culture may still be essentially free of the specified serum even though a discrete component (e.g.
bovine serum albumin) has been isolated from serum and then is exogenously supplied. The point is that when serum itself is added the variability concerns arise.
However, when one or more well defined purified component(s) of such serum is added, they do not.
Preferably the primate embryonic stem cells that are cultured using this method are human embryonic stem cells that are true ES cell lines in that they: (i) are capable of indefinite proliferation in vitro in an undifferentiated state; (ii) are capable of differentiation to derivatives of all three embryonic germ layers (endoderm, mesoderm, and ectoderm) even after prolonged culture; and (iii) maintain a normal karyotype throughout prolonged culture. They are therefore referred to as being pluripotent.
The culturing permits the embryonic stem cells to stably proliferate in culture for over one month (preferably over six months; even more preferably over twelve months) while maintaining the potential of the stem cells to differentiate into derivatives of endoderm, mesoderm, and ectoderm tissues, and while maintaining the karyotype of the stem cells.
In another aspect the invention provides another method of culturing primate embryonic stem cells. One cultures the stem cells in a culture essentially free of mammalian fetal serum (preferably also essentially free of any animal serum) and in the presence of a growth factor capable of activating a fibroblast growth factor signaling receptor, wherein the growth factor is supplied from a source other than just a fibroblast feeder layer.
While the growth factor is preferably a fibroblast growth 5 factor, it might also be other materials such as certain synthetic small peptides (e.g. produced by recombinant DNA variants or mutants) designed to activate fibroblast growth factor receptors. See generally T. Yamaguchi, al., 152 Dev. Biol. 75-88 (1992)(signaling receptors).
In yet another aspect the invention provides a culture system for culturing primate embryonic stem cells. It has a fibroblast feeder layer and human basic fibroblast growth factor supplied by other than just the fibrolI,last feeder layer. The culture system is essentially free of animal serum.
Yet another aspect of the invention provides cell lines (preferably cloned cell lines) derived using the above method. "Derived" is used in its broadest sense to cover directly or indirectly derived lines.
Variability in results due to differences in batches of animal serum is thereby avoided. Further, it has been discovered that avoiding use of animal serum while using fibroblast growth factor can increase the efficiency of cloning.
It is therefore an advantage of the present invention to provide culture conditions for primate embryonic stem cell lines where the conditions are less variable and permit more efficient cloning. Other advantages of the present invention will become apparent after study of the specification and claims.
5a In yet another aspect the invention provides a method of culturing primate embryonic stem cells in defined media without serum, the method comprising culturing the primate embryonic stem cells in a culture medium containing albumin, amino acids, vitamins, minerals, at least one transferrin or transferrin substitute, and at least one insulin or insulin substitute, the culture medium being essentially free of mammalian fetal serum and containing exogenously supplied human fibroblast growth factor that is supplied from a source other than just a fibroblast feeder layer, so that the stem cells proliferate in culture and remain undifferentiated in the absence of serum in the medium.
In yet another aspect the invention provides a method of culturing primate embryonic stem cells in defined media without serum, the method comprising culturing the primate embryonic stem cells in a culture medium containing albumin, amino acids, vitamins, minerals, at least one transferrin or transferrin substitute, and at least one insulin or insulin substitute, the culture medium being essentially free of mammalian fetal serum and containing exogenously supplied mammalian fibroblast growth factor that is supplied from a source other than just a fibroblast feeder layer, said culturing step being conducted for over one month with the embryonic stem cells proliferating in culture while maintaining the potential of the stem cells to differentiate into derivatives of endoderm, mesoderm, and ectoderm tissues, and while maintaining the karyotype of the stem cells.
In yet another aspect the invention provides a method of culturing primate embryonic stem cells in defined media without serum, the method comprising culturing the primate embryonic stem cells in a culture 5b medium containing albumin, amino acids, vitamins, minerals, at least one transferrin or transferrin substitute, and at least one insulin or insulin substitute, the culture medium being essentially free of mammalian fetal serum and in the presence of a fibroblast growth factor capable of activating a fibroblast growth factor signaling receptor, wherein the growth factor is exogenously supplied to the culture from a source other than just a fibroblast feeder layer, said culturing step being conducted for over one month with the embryonic stem cells proliferating in culture while maintaining the potential of the stem cells to differentiate into derivatives of endoderm, mesoderm, and ectoderm tissues, and while maintaining the karyotype of the stem cells.
In yet another aspect the invention provides a method of culturing primate embryonic stem cells without serum, the improvement comprising culturing the primate embryonic stem cells in a culture free of added mammalian fetal serum but including albumin, vitamins, minerals, insulin, and transferrin, and in the presence of fibroblast growth factor that is exogenously supplied to the culture from a source other than just a fibroblast feeder layer, so that the stem cells proliferate in culture and remain undifferentiated in the absence of serum in the medium.
In yet another aspect the invention provides a method of culturing primate embryonic stem cells in defined media without serum, the method comprising culturing the stem cells in a culture medium containing albumin, amino acids, vitamins, minerals, at least one transferrin or transferrin substitute, and at lease one insulin or insulin substitute, the culture medium being essentially free of mammalian fetal serum and in the presence of a fibroblast growth factor capable of 5c activating a fibroblast growth factor signaling receptor, wherein the growth factor is exogenously supplied to the culture from a source other than just a fibroblast feeder layer, so that the stem cells proliferate in culture and remain undifferentiated in the absence of serum in the medium.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
In the following experiments I used the methods and culture systems of the invention to culture human ES cell lines. Two clonally derived human ES cell lines proliferated for over eight months after clonal derivation and maintained the ability to differentiate to advanced derivatives of all three embryonic germ layers.
Techniques for the initial derivation, culture, and characterization of the human ES cell line H9 were described in J. Thomson et al., 282 Science 1145-1147 (1998). In my experiments herein human ES cells were then plated on irradiated (35 gray gamma irradiation) mouse embryonic fibroblast. Culture medium for the present work consisted of 80% "KnockOut" Dulbeco's modified Eagle's medium (DMEM) (Gibco BRL, Rockville, MD), 1 mM L-Glutamine, 0.1 mM R-mercaptoethanol, and 1%
nonessential amino acids stock (Gibco BRL, Rockville, MD), supplemented with either 20% fetal bovine serum (HyClone, Logan, UT) or 20% KnockOut SR, a serum-free replacement originally optimized for mouse ES cells (Gibco BRL, Rockville, MD). The components of KnockOut SR are those described for serum replacements in WO
98/30679.
In alternative experiments medium was supplemented with either serum or the aforesaid serum replacer KnockOut SR, and either with or without human recombinant basic fibroblast growth factor (bFGF, 4 ng/ml). The preferred concentration range of bFGF in the culture is between .1 ng/ml to 500 ng/ml.
To determine cloning efficiency under varying culture conditions, H-9 cultures were dissociated to single cells for 7 minutes with 0.05% trypsin/0.25% EDTA, washed by centrifugation, and plated on mitotically inactivated mouse embryonic fibroblasts (105. ES cells per well of a 6-well plate). To confirm growth from single cells for the derivation of clonal ES cell lines, individual cells were selected by direct observation under a stereomicroscope and transferred by micropipette to individual wells of a 96 well plate containing mouse embryonic fibroblasts feeders with medium containing 20%
serum replacer and 4 ng/ml bFGF.
Clones were expanded by routine passage every 5-7 days with 1 mg/ml collagenase type IV (Gibco BRL, Rockville, MD).' Six months after derivation, H9 cells exhibited a normal XX karyotype by standard G-banding techniques (20 chromosomal spreads analyzed). However, seven months after derivation, in a single karyotype preparation, 16/20 chromosomal spreads exhibited a normal XX karyotype, but 4/20 spreads demonstrated random abnormalities, including one with a translocation to chromosome 13 short arm, one with an inverted chromosome 20, one with a translocation to the number 4 short arm, and one with multiple fragmentation. Subsequently, at 8, 10, and 12.75 months after derivation, H9 cells exhibited normal karyotypes in all 20 chromosomal spreads examined.
We observed that the cloning efficiency of human ES
cells in previously described culture conditions that included animal serum was poor (regardless of the presence or absence of bFGF). We also observed that in the absence of animal serum the cloning efficiency increased, and increased even more with bFGF.
The data expressed below is the total number of colonies resulting from 105 individualized ES cells plated, +/- standard error of the mean (percent colony cloning efficiency). With 20% fetal serum and no bFGF
there was a result of 240 +/- 28. With 20% serum and bFGF the result was about the same, 260 +/- 12. In the absence of the serum (presence of 20% serum replacer) the result with no bFGF was 633 +/- 43 and the result with bFGF was 826 +/- 61. Thus, serum adversely affected cloning efficiency, and the presence of the bFGF in the absence of serum had an added synergistic benefit insofar as cloning efficiency.
The long term culture of human ES cells in the presence of serum does not require the addition of exogenously supplied bFGF, and (as noted above) the addition of bFGF to serum-containing medium does not significantly increase human ES cell cloning efficiency.
However, in serum-free medium, bFGF increased the initial cloning efficiency of human ES cells.
Further, I have discovered that supplying exogenous bFGF is very important for continued undifferentiated proliferation of primate embryonic stem cells in the absence of animal serum. In serum-free medium lacking exogenous bFGF, human ES cells uniformly differentiated by two weeks of culture. Addition of other factors such as LIF (in the absence of bFGF) did not prevent the differentiation.
The results perceived are particularly applicable to clonal lines. In this regard, clones for expansion were selected by placing cells individually into wells of a 96 well plate under direct microscopic observation. Of 192 H-9 cells plated into wells of 96 well plates, two clones were successfully expanded (H-9.1 and H-9.2). Both of these clones were subsequently cultured continuously in media supplemented with serum replacer and bFGF.
H9.1 and H9.2 cells both maintained a normal XX
karyotype even after more than 8 months of continuous culture after cloning. The H-9.1 and H-9.2 clones maintained the potential to form derivatives of all three embryonic germ layers even after long term culture in serum-free medium. After 6 months of culture, H9.1 and H9.2 clones were confirmed to have normal karyotypes and were then injected into SLID-beige mice.
Both H9.1 and H9.2 cells formed teratomas that contained derivatives of all three embryonic germ layers including gut epithelium (endoderm) embryonic kidney, striated muscle, smooth muscle, bone, cartilage (mesoderm), and neural tissue (ectoderm). The range of differentiation observed within the teratomas of the high passage H9.1 and H9.2 cells was comparable to that observed in teratomas formed by low passage parental H9 cells.
It should be appreciated from the description above that while animal serum is supportive of growth it is a complex mixture that can contain compounds both beneficial and detrimental to human ES cell culture.
Moreover, different serum batches vary widely in their ability to support vigorous undifferentiated proliferation of human ES cells. Replacing serum with a clearly defined component reduces the variability of results associated with this serum batch variation, and should allow more carefully defined differentiation studies.
Further, the lower cloning efficiency in medium containing serum suggests the presence of compounds in conventionally used serum that are detrimental to stem cell survival, particularly when the cells are dispersed to single cells. Avoiding the use of these compounds is therefore highly desired.
The present invention has been described above with respect to its preferred embodiments. Other forms of this concept are also intended to be within the scope of the, claims. For example, while recombinantly produced human basic fibroblast growth factor was used in the above experiments, naturally isolated fibroblast growth factor should also be suitable. Further, these techniques should also prove suitable for use on monkey and other primate cell cultures.
Thus, the claims should be looked to in order to judge the full scope of the invention.
Industrial Applicability The present invention provides methods for culturing primate embryonic stem cells, and culture media for use therewith.
Long term proliferative capacity, developmental potential after prolonged culture, and karyotypic stability are key features with respect to the utility of primate embryonic stem cell cultures. Cultures of such cells (especially on fibroblast feeder layers) have typically been supplemented with animal serum (especially fetal bovine serum) to permit the desired proliferation during such culturing.
For example, in U.S. patents 5,453,357, 5,670,372 and 5,690,296 various culture conditions were described, including some using a type of basic fibroblast growth factor together with animal serum. Unfortunately, serum tends to have variable properties from batch to batch, thus affecting culture characteristics.
In WO 98/30679 there was a discussion of providing a serum-free supplement in replacement for animal serum to support the growth of certain embryonic stem cells in culture. The serum replacement included albumins or albumin substitutes, one or more amino acids, one or more vitamins, one or more transferrins or transferrin substitutes, one or more antioxidants, one or more insulins or insulin substitutes, one or more collagen precursors, and one or more trace elements. It was noted that this replacement could be further supplemented with leukemia inhibitory factor, steel factor, or ciliary neurotrophic factor. Unfortunately, in the context of primate embryonic stem cell cultures (especially those grown on fibroblast feeder layers), these culture media did not prove satisfactory.
In the context of nutrient serum culture media (e.g.
fetal bovine serum), WO 99/20741 discusses the benefit of use of various growth factors such as bFGF in culturing primate stem cells. However, culture media without nutrient serum is not described.
In U.S. patent 5,405,772 growth medium for hematopoietic cells and bone marrow stromal cells are described. There is a suggestion to use fibroblast growth factor in a serum-deprived media for this purpose.
However, conditions for growth primate of embryonic stem cells are not described.
It can therefore be seen that a need still exists for techniques to stably culture primate embryonic stem cells without the requirement for use of animal serum.
BRIEF SUMMARY OF THE INVENTION
In one aspect the invention provides a method of culturing primate embryonic stem cells. One cultures the stem cells in a culture essentially free of mammalian fetal serum (preferably also essentially free of any animal serum) and in the presence of fibroblast growth factor that is supplied from a source other than just a fibroblast feeder layer. In a preferred form the culture also has a fibroblast feeder layer.
Fibroblast growth factors are essential molecules for mammalian development. There are currently nine known fibroblast growth factor ligands and four signaling fibroblast growth factor receptors therefor (and their spliced variants). See generally D. Ornitz et al., 25 J.
Biol. Chem. 15292-7 (1996); U.S. patent 5,453,357.
Slight variations in these factors are expected to exist between species, and thus the term fibroblast growth factor is not species limited. However, I prefer to use human fibroblast growth factors, more preferably human basic fibroblast growth factor produced from a recombinant gene. This compound is readily available in quantity from Gibco BRL-Life Technologies and others.
It should be noted that for purposes of this patent the culture may still be essentially free of the specified serum even though a discrete component (e.g.
bovine serum albumin) has been isolated from serum and then is exogenously supplied. The point is that when serum itself is added the variability concerns arise.
However, when one or more well defined purified component(s) of such serum is added, they do not.
Preferably the primate embryonic stem cells that are cultured using this method are human embryonic stem cells that are true ES cell lines in that they: (i) are capable of indefinite proliferation in vitro in an undifferentiated state; (ii) are capable of differentiation to derivatives of all three embryonic germ layers (endoderm, mesoderm, and ectoderm) even after prolonged culture; and (iii) maintain a normal karyotype throughout prolonged culture. They are therefore referred to as being pluripotent.
The culturing permits the embryonic stem cells to stably proliferate in culture for over one month (preferably over six months; even more preferably over twelve months) while maintaining the potential of the stem cells to differentiate into derivatives of endoderm, mesoderm, and ectoderm tissues, and while maintaining the karyotype of the stem cells.
In another aspect the invention provides another method of culturing primate embryonic stem cells. One cultures the stem cells in a culture essentially free of mammalian fetal serum (preferably also essentially free of any animal serum) and in the presence of a growth factor capable of activating a fibroblast growth factor signaling receptor, wherein the growth factor is supplied from a source other than just a fibroblast feeder layer.
While the growth factor is preferably a fibroblast growth 5 factor, it might also be other materials such as certain synthetic small peptides (e.g. produced by recombinant DNA variants or mutants) designed to activate fibroblast growth factor receptors. See generally T. Yamaguchi, al., 152 Dev. Biol. 75-88 (1992)(signaling receptors).
In yet another aspect the invention provides a culture system for culturing primate embryonic stem cells. It has a fibroblast feeder layer and human basic fibroblast growth factor supplied by other than just the fibrolI,last feeder layer. The culture system is essentially free of animal serum.
Yet another aspect of the invention provides cell lines (preferably cloned cell lines) derived using the above method. "Derived" is used in its broadest sense to cover directly or indirectly derived lines.
Variability in results due to differences in batches of animal serum is thereby avoided. Further, it has been discovered that avoiding use of animal serum while using fibroblast growth factor can increase the efficiency of cloning.
It is therefore an advantage of the present invention to provide culture conditions for primate embryonic stem cell lines where the conditions are less variable and permit more efficient cloning. Other advantages of the present invention will become apparent after study of the specification and claims.
5a In yet another aspect the invention provides a method of culturing primate embryonic stem cells in defined media without serum, the method comprising culturing the primate embryonic stem cells in a culture medium containing albumin, amino acids, vitamins, minerals, at least one transferrin or transferrin substitute, and at least one insulin or insulin substitute, the culture medium being essentially free of mammalian fetal serum and containing exogenously supplied human fibroblast growth factor that is supplied from a source other than just a fibroblast feeder layer, so that the stem cells proliferate in culture and remain undifferentiated in the absence of serum in the medium.
In yet another aspect the invention provides a method of culturing primate embryonic stem cells in defined media without serum, the method comprising culturing the primate embryonic stem cells in a culture medium containing albumin, amino acids, vitamins, minerals, at least one transferrin or transferrin substitute, and at least one insulin or insulin substitute, the culture medium being essentially free of mammalian fetal serum and containing exogenously supplied mammalian fibroblast growth factor that is supplied from a source other than just a fibroblast feeder layer, said culturing step being conducted for over one month with the embryonic stem cells proliferating in culture while maintaining the potential of the stem cells to differentiate into derivatives of endoderm, mesoderm, and ectoderm tissues, and while maintaining the karyotype of the stem cells.
In yet another aspect the invention provides a method of culturing primate embryonic stem cells in defined media without serum, the method comprising culturing the primate embryonic stem cells in a culture 5b medium containing albumin, amino acids, vitamins, minerals, at least one transferrin or transferrin substitute, and at least one insulin or insulin substitute, the culture medium being essentially free of mammalian fetal serum and in the presence of a fibroblast growth factor capable of activating a fibroblast growth factor signaling receptor, wherein the growth factor is exogenously supplied to the culture from a source other than just a fibroblast feeder layer, said culturing step being conducted for over one month with the embryonic stem cells proliferating in culture while maintaining the potential of the stem cells to differentiate into derivatives of endoderm, mesoderm, and ectoderm tissues, and while maintaining the karyotype of the stem cells.
In yet another aspect the invention provides a method of culturing primate embryonic stem cells without serum, the improvement comprising culturing the primate embryonic stem cells in a culture free of added mammalian fetal serum but including albumin, vitamins, minerals, insulin, and transferrin, and in the presence of fibroblast growth factor that is exogenously supplied to the culture from a source other than just a fibroblast feeder layer, so that the stem cells proliferate in culture and remain undifferentiated in the absence of serum in the medium.
In yet another aspect the invention provides a method of culturing primate embryonic stem cells in defined media without serum, the method comprising culturing the stem cells in a culture medium containing albumin, amino acids, vitamins, minerals, at least one transferrin or transferrin substitute, and at lease one insulin or insulin substitute, the culture medium being essentially free of mammalian fetal serum and in the presence of a fibroblast growth factor capable of 5c activating a fibroblast growth factor signaling receptor, wherein the growth factor is exogenously supplied to the culture from a source other than just a fibroblast feeder layer, so that the stem cells proliferate in culture and remain undifferentiated in the absence of serum in the medium.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
In the following experiments I used the methods and culture systems of the invention to culture human ES cell lines. Two clonally derived human ES cell lines proliferated for over eight months after clonal derivation and maintained the ability to differentiate to advanced derivatives of all three embryonic germ layers.
Techniques for the initial derivation, culture, and characterization of the human ES cell line H9 were described in J. Thomson et al., 282 Science 1145-1147 (1998). In my experiments herein human ES cells were then plated on irradiated (35 gray gamma irradiation) mouse embryonic fibroblast. Culture medium for the present work consisted of 80% "KnockOut" Dulbeco's modified Eagle's medium (DMEM) (Gibco BRL, Rockville, MD), 1 mM L-Glutamine, 0.1 mM R-mercaptoethanol, and 1%
nonessential amino acids stock (Gibco BRL, Rockville, MD), supplemented with either 20% fetal bovine serum (HyClone, Logan, UT) or 20% KnockOut SR, a serum-free replacement originally optimized for mouse ES cells (Gibco BRL, Rockville, MD). The components of KnockOut SR are those described for serum replacements in WO
98/30679.
In alternative experiments medium was supplemented with either serum or the aforesaid serum replacer KnockOut SR, and either with or without human recombinant basic fibroblast growth factor (bFGF, 4 ng/ml). The preferred concentration range of bFGF in the culture is between .1 ng/ml to 500 ng/ml.
To determine cloning efficiency under varying culture conditions, H-9 cultures were dissociated to single cells for 7 minutes with 0.05% trypsin/0.25% EDTA, washed by centrifugation, and plated on mitotically inactivated mouse embryonic fibroblasts (105. ES cells per well of a 6-well plate). To confirm growth from single cells for the derivation of clonal ES cell lines, individual cells were selected by direct observation under a stereomicroscope and transferred by micropipette to individual wells of a 96 well plate containing mouse embryonic fibroblasts feeders with medium containing 20%
serum replacer and 4 ng/ml bFGF.
Clones were expanded by routine passage every 5-7 days with 1 mg/ml collagenase type IV (Gibco BRL, Rockville, MD).' Six months after derivation, H9 cells exhibited a normal XX karyotype by standard G-banding techniques (20 chromosomal spreads analyzed). However, seven months after derivation, in a single karyotype preparation, 16/20 chromosomal spreads exhibited a normal XX karyotype, but 4/20 spreads demonstrated random abnormalities, including one with a translocation to chromosome 13 short arm, one with an inverted chromosome 20, one with a translocation to the number 4 short arm, and one with multiple fragmentation. Subsequently, at 8, 10, and 12.75 months after derivation, H9 cells exhibited normal karyotypes in all 20 chromosomal spreads examined.
We observed that the cloning efficiency of human ES
cells in previously described culture conditions that included animal serum was poor (regardless of the presence or absence of bFGF). We also observed that in the absence of animal serum the cloning efficiency increased, and increased even more with bFGF.
The data expressed below is the total number of colonies resulting from 105 individualized ES cells plated, +/- standard error of the mean (percent colony cloning efficiency). With 20% fetal serum and no bFGF
there was a result of 240 +/- 28. With 20% serum and bFGF the result was about the same, 260 +/- 12. In the absence of the serum (presence of 20% serum replacer) the result with no bFGF was 633 +/- 43 and the result with bFGF was 826 +/- 61. Thus, serum adversely affected cloning efficiency, and the presence of the bFGF in the absence of serum had an added synergistic benefit insofar as cloning efficiency.
The long term culture of human ES cells in the presence of serum does not require the addition of exogenously supplied bFGF, and (as noted above) the addition of bFGF to serum-containing medium does not significantly increase human ES cell cloning efficiency.
However, in serum-free medium, bFGF increased the initial cloning efficiency of human ES cells.
Further, I have discovered that supplying exogenous bFGF is very important for continued undifferentiated proliferation of primate embryonic stem cells in the absence of animal serum. In serum-free medium lacking exogenous bFGF, human ES cells uniformly differentiated by two weeks of culture. Addition of other factors such as LIF (in the absence of bFGF) did not prevent the differentiation.
The results perceived are particularly applicable to clonal lines. In this regard, clones for expansion were selected by placing cells individually into wells of a 96 well plate under direct microscopic observation. Of 192 H-9 cells plated into wells of 96 well plates, two clones were successfully expanded (H-9.1 and H-9.2). Both of these clones were subsequently cultured continuously in media supplemented with serum replacer and bFGF.
H9.1 and H9.2 cells both maintained a normal XX
karyotype even after more than 8 months of continuous culture after cloning. The H-9.1 and H-9.2 clones maintained the potential to form derivatives of all three embryonic germ layers even after long term culture in serum-free medium. After 6 months of culture, H9.1 and H9.2 clones were confirmed to have normal karyotypes and were then injected into SLID-beige mice.
Both H9.1 and H9.2 cells formed teratomas that contained derivatives of all three embryonic germ layers including gut epithelium (endoderm) embryonic kidney, striated muscle, smooth muscle, bone, cartilage (mesoderm), and neural tissue (ectoderm). The range of differentiation observed within the teratomas of the high passage H9.1 and H9.2 cells was comparable to that observed in teratomas formed by low passage parental H9 cells.
It should be appreciated from the description above that while animal serum is supportive of growth it is a complex mixture that can contain compounds both beneficial and detrimental to human ES cell culture.
Moreover, different serum batches vary widely in their ability to support vigorous undifferentiated proliferation of human ES cells. Replacing serum with a clearly defined component reduces the variability of results associated with this serum batch variation, and should allow more carefully defined differentiation studies.
Further, the lower cloning efficiency in medium containing serum suggests the presence of compounds in conventionally used serum that are detrimental to stem cell survival, particularly when the cells are dispersed to single cells. Avoiding the use of these compounds is therefore highly desired.
The present invention has been described above with respect to its preferred embodiments. Other forms of this concept are also intended to be within the scope of the, claims. For example, while recombinantly produced human basic fibroblast growth factor was used in the above experiments, naturally isolated fibroblast growth factor should also be suitable. Further, these techniques should also prove suitable for use on monkey and other primate cell cultures.
Thus, the claims should be looked to in order to judge the full scope of the invention.
Industrial Applicability The present invention provides methods for culturing primate embryonic stem cells, and culture media for use therewith.
Claims (20)
1. A method of culturing primate embryonic stem cells in defined media without serum, the method comprising:
culturing the primate embryonic stem cells in a culture medium containing albumin, amino acids, vitamins, minerals, at least one transferrin or transferrin substitute, and at least one insulin or insulin substitute, the culture medium being essentially free of mammalian fetal serum and containing exogenously supplied human fibroblast growth factor that is supplied from a source other than just a fibroblast feeder layer, so that the stem cells proliferate in culture and remain undifferentiated in the absence of serum in the medium.
culturing the primate embryonic stem cells in a culture medium containing albumin, amino acids, vitamins, minerals, at least one transferrin or transferrin substitute, and at least one insulin or insulin substitute, the culture medium being essentially free of mammalian fetal serum and containing exogenously supplied human fibroblast growth factor that is supplied from a source other than just a fibroblast feeder layer, so that the stem cells proliferate in culture and remain undifferentiated in the absence of serum in the medium.
2. The method of claim 1, wherein the culture is essentially free of any animal serum.
3. The method of claim 2, wherein the culture also comprises a fibroblast feeder layer.
4. The method of claim 2, wherein the fibroblast growth factor is basic fibroblast growth factor.
5. The method of claim 4, wherein the fibroblast growth factor is human basic fibroblast growth factor which has been produced from a recombinant gene.
6. The method of claim 5, wherein the human basic fibroblast growth factor is present in the culture in a concentration of at least 0.1 ng/ml for at least a portion of the method.
7. The method of claim 2, wherein the primate embryonic stem cells are human embryonic stem cells.
8. A method of culturing primate embryonic stem cells in defined media without serum, the method comprising:
culturing the primate embryonic stem cells in a culture medium containing albumin, amino acids, vitamins, minerals, at least one transferrin or transferrin substitute, and at least one insulin or insulin substitute, the culture medium being essentially free of mammalian fetal serum and containing exogenously supplied mammalian fibroblast growth factor that is supplied from a source other than just a fibroblast feeder layer, said culturing step being conducted for over one month with the embryonic stem cells proliferating in culture while maintaining the potential of the stem cells to differentiate into derivatives of endoderm, mesoderm, and ectoderm tissues, and while maintaining the karyotype of the stem cells.
culturing the primate embryonic stem cells in a culture medium containing albumin, amino acids, vitamins, minerals, at least one transferrin or transferrin substitute, and at least one insulin or insulin substitute, the culture medium being essentially free of mammalian fetal serum and containing exogenously supplied mammalian fibroblast growth factor that is supplied from a source other than just a fibroblast feeder layer, said culturing step being conducted for over one month with the embryonic stem cells proliferating in culture while maintaining the potential of the stem cells to differentiate into derivatives of endoderm, mesoderm, and ectoderm tissues, and while maintaining the karyotype of the stem cells.
9. A method of culturing primate embryonic stem cells in defined media without serum, the method comprising:
culturing the stem cells in a culture medium containing albumin, amino acids, vitamins, minerals, at least one transferrin or transferrin substitute, and at lease one insulin or insulin substitute, the culture medium being essentially free of mammalian fetal serum and in the presence of a fibroblast growth factor capable of activating a fibroblast growth factor signaling receptor, wherein the growth factor is exogenously supplied to the culture from a source other than just a fibroblast feeder layer, so that the stem cells proliferate in culture and remain undifferentiated in the absence of serum in the medium.
culturing the stem cells in a culture medium containing albumin, amino acids, vitamins, minerals, at least one transferrin or transferrin substitute, and at lease one insulin or insulin substitute, the culture medium being essentially free of mammalian fetal serum and in the presence of a fibroblast growth factor capable of activating a fibroblast growth factor signaling receptor, wherein the growth factor is exogenously supplied to the culture from a source other than just a fibroblast feeder layer, so that the stem cells proliferate in culture and remain undifferentiated in the absence of serum in the medium.
10. The method of claim 9, wherein the culture is essentially free of any animal serum.
11. The method of claim 10, wherein the culture also comprises a fibroblast feeder layer.
12. The method of claim 10, wherein the primate embryonic stem cells are human embryonic stem cells.
13. A method of culturing primate embryonic stem cells in defined media without serum, the method comprising:
culturing the primate embryonic stem cells in a culture medium containing albumin, amino acids, vitamins, minerals, at least one transferrin or transferrin substitute, and at least one insulin or insulin substitute, the culture medium being essentially free of mammalian fetal serum and in the presence of a fibroblast growth factor capable of activating a fibroblast growth factor signaling receptor, wherein the growth factor is exogenously supplied to the culture from a source other than just a fibroblast feeder layer, said culturing step being conducted for over one month with the embryonic stem cells proliferating in culture while maintaining the potential of the stem cells to differentiate into derivatives of endoderm, mesoderm, and ectoderm tissues, and while maintaining the karyotype of the stem cells.
culturing the primate embryonic stem cells in a culture medium containing albumin, amino acids, vitamins, minerals, at least one transferrin or transferrin substitute, and at least one insulin or insulin substitute, the culture medium being essentially free of mammalian fetal serum and in the presence of a fibroblast growth factor capable of activating a fibroblast growth factor signaling receptor, wherein the growth factor is exogenously supplied to the culture from a source other than just a fibroblast feeder layer, said culturing step being conducted for over one month with the embryonic stem cells proliferating in culture while maintaining the potential of the stem cells to differentiate into derivatives of endoderm, mesoderm, and ectoderm tissues, and while maintaining the karyotype of the stem cells.
14. In a method of culturing primate embryonic stem cells without serum, the improvement comprising:
culturing the primate embryonic stem cells in a culture free of added mammalian fetal serum but including albumin, vitamins, minerals, insulin, and transferrin, and in the presence of fibroblast growth factor that is exogenously supplied to the culture from a source other than just a fibroblast feeder layer, so that the stem cells proliferate in culture and remain undifferentiated in the absence of serum in the medium.
culturing the primate embryonic stem cells in a culture free of added mammalian fetal serum but including albumin, vitamins, minerals, insulin, and transferrin, and in the presence of fibroblast growth factor that is exogenously supplied to the culture from a source other than just a fibroblast feeder layer, so that the stem cells proliferate in culture and remain undifferentiated in the absence of serum in the medium.
15. A method of establishing a clonal human embryonic stem cell line capable of sustaining a phenotype of normal embryonic stem cells following prolonged in vitro culture, the method comprising the steps of providing a culture of undifferentiated human embryonic stem cells; removing an individual undifferentiated human embryonic stem cell in a separate culture which includes at least about 4 ng/ml of exogenously supplied human fibroblast growth factor and which is essentially free of mammalian serum; and culturing the individual undifferentiated cell in a serum-free medium which includes at least about 4 ng/ml of exogenously supplied human fibroblast growth factor such that the cell expands into a clonal culture of undifferentiated human embryonic stem cells maintaining the ability to differentiate into endoderm, mesoderm and ectoderm after at least six months of culture.
16. The method of claim 15 wherein the clonal culture of human embryonic stem cells is maintained for over twelve months.
17. The method of claim 15 wherein in the culturing step the serum-free medium contains collagenase.
18. The method of claim 17 wherein the collagenase is collagenase type IV.
19. The method of claim 17 wherein the concentration of collagenase is 1 mg/ml.
20. A method of establishing a clonal human embryonic stem cell line capable of sustaining a phenotype of normal embryonic stem cells following prolonged in vitro culture, the method comprising the steps of providing a culture of undifferentiated human embryonic stem cells; removing an individual undifferentiated human embryonic stem cell from the culture and placing the individual cell in a separate culture which includes at least about 4 ng/ml of basic human fibroblast growth factor and mouse embryonic feeder cells but is essentially free of mammalian serum; and culturing the cell in the separate culture such that the cell expands into a clonal culture of undifferentiated human embryonic stem cells which can maintain the ability to differentiate into endoderm, mesoderm and ectoderm after at least eight months of culture.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/522,030 US7005252B1 (en) | 2000-03-09 | 2000-03-09 | Serum free cultivation of primate embryonic stem cells |
| US09/522,030 | 2000-03-09 | ||
| PCT/US2001/006912 WO2001066697A2 (en) | 2000-03-09 | 2001-03-02 | Serum free cultivation of primate embryonic stem cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2402299A1 CA2402299A1 (en) | 2001-09-13 |
| CA2402299C true CA2402299C (en) | 2012-12-18 |
Family
ID=24079156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2402299A Expired - Lifetime CA2402299C (en) | 2000-03-09 | 2001-03-02 | Serum free cultivation of primate embryonic stem cells |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US7005252B1 (en) |
| EP (1) | EP1261691B1 (en) |
| JP (3) | JP5717311B2 (en) |
| KR (1) | KR100795760B1 (en) |
| CN (1) | CN100372928C (en) |
| AU (2) | AU2001241973B2 (en) |
| BR (1) | BR0108507A (en) |
| CA (1) | CA2402299C (en) |
| HK (1) | HK1053616A1 (en) |
| IL (2) | IL151270A0 (en) |
| IS (1) | IS6515A (en) |
| MX (1) | MXPA02008698A (en) |
| NO (1) | NO335780B1 (en) |
| NZ (1) | NZ520701A (en) |
| WO (1) | WO2001066697A2 (en) |
Families Citing this family (151)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7410798B2 (en) | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
| US7413904B2 (en) * | 1998-10-23 | 2008-08-19 | Geron Corporation | Human embryonic stem cells having genetic modifications |
| US10638734B2 (en) | 2004-01-05 | 2020-05-05 | Abt Holding Company | Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
| US8252280B1 (en) | 1999-08-05 | 2012-08-28 | Regents Of The University Of Minnesota | MAPC generation of muscle |
| US7015037B1 (en) | 1999-08-05 | 2006-03-21 | Regents Of The University Of Minnesota | Multiponent adult stem cells and methods for isolation |
| US7838289B2 (en) | 2001-02-14 | 2010-11-23 | Abt Holding Company | Assay utilizing multipotent adult stem cells |
| US7455983B2 (en) * | 2000-01-11 | 2008-11-25 | Geron Corporation | Medium for growing human embryonic stem cells |
| US20100173410A1 (en) * | 2000-03-09 | 2010-07-08 | Wicell Research Institute, Inc. | Cultivation of Primate Embryonic Stem Cells |
| US7439064B2 (en) * | 2000-03-09 | 2008-10-21 | Wicell Research Institute, Inc. | Cultivation of human embryonic stem cells in the absence of feeder cells or without conditioned medium |
| WO2003008535A2 (en) * | 2001-07-20 | 2003-01-30 | Technion Research And Development Foundation Ltd. | Methods of generating human cardiac cells and tissues and uses thereof |
| WO2003046129A2 (en) * | 2001-11-09 | 2003-06-05 | Trustees Of The University Of Pennsylvania | Compositions for the derivation of germ cells from stem cells and methods of use thereof |
| GB0202149D0 (en) | 2002-01-30 | 2002-03-20 | Univ Edinburgh | Pluripotency determining factors and uses thereof |
| US20040111285A1 (en) * | 2002-04-09 | 2004-06-10 | Mark Germain | Method for human pluripotent stem cells |
| AU2003260724A1 (en) * | 2002-08-22 | 2004-03-11 | Celltran Limited | Cell culture surface |
| AU2002344527A1 (en) * | 2002-10-25 | 2004-05-13 | Hunan Hui-Lin Life Technology Co. | The feeder cell layer for in vitro culturing human embryonic stem cells and the method for culturing embryonic stem cells |
| GB0304918D0 (en) * | 2003-03-05 | 2003-04-09 | Celltran Ltd | Cell culture |
| US7820439B2 (en) | 2003-09-03 | 2010-10-26 | Reliance Life Sciences Pvt Ltd. | In vitro generation of GABAergic neurons from pluripotent stem cells |
| US20070269412A1 (en) | 2003-12-02 | 2007-11-22 | Celavie Biosciences, Llc | Pluripotent cells |
| WO2005056755A2 (en) | 2003-12-02 | 2005-06-23 | Catholic Healthcare West | Compositions and methods for propagation of neural progenitor cells |
| US7985585B2 (en) | 2004-07-09 | 2011-07-26 | Viacyte, Inc. | Preprimitive streak and mesendoderm cells |
| US20050266554A1 (en) * | 2004-04-27 | 2005-12-01 | D Amour Kevin A | PDX1 expressing endoderm |
| EP1709159B1 (en) | 2003-12-23 | 2019-05-15 | Viacyte, Inc. | Definitive endoderm |
| US7541185B2 (en) * | 2003-12-23 | 2009-06-02 | Cythera, Inc. | Methods for identifying factors for differentiating definitive endoderm |
| US8647873B2 (en) | 2004-04-27 | 2014-02-11 | Viacyte, Inc. | PDX1 expressing endoderm |
| US7625753B2 (en) * | 2003-12-23 | 2009-12-01 | Cythera, Inc. | Expansion of definitive endoderm cells |
| US8586357B2 (en) * | 2003-12-23 | 2013-11-19 | Viacyte, Inc. | Markers of definitive endoderm |
| US20050233446A1 (en) * | 2003-12-31 | 2005-10-20 | Parsons Xuejun H | Defined media for stem cell culture |
| US20080085554A1 (en) * | 2004-02-13 | 2008-04-10 | Norio Nakatsuji | Culture Medium for Culturing Feeder Cells for Embryonic Stem Cells Culture and the Prepared Feeder Cells |
| SG150567A1 (en) | 2004-03-23 | 2009-03-30 | Akaike Toshihiro | Pluripotent stem cell growing method |
| EP2377922B1 (en) | 2004-04-27 | 2020-04-08 | Viacyte, Inc. | PDX1 expressing endoderm |
| EP1749091B1 (en) * | 2004-05-21 | 2013-07-31 | Wicell Research Institute, Inc. | Feeder independent extended culture of embryonic stem cells |
| CA2573354C (en) | 2004-07-09 | 2015-02-24 | Cythera, Inc. | Preprimitive streak and mesendoderm cells |
| MX2007001772A (en) * | 2004-08-13 | 2007-07-11 | Univ Georgia Res Found | Compositions and methods for self-renewal and differentiation in human embryonic stem cells. |
| CN101044235B (en) | 2004-09-08 | 2013-01-02 | 威斯康星校友研究基金会 | Culturing human embryonic stem cells |
| ES2800973T3 (en) * | 2004-09-28 | 2021-01-07 | Wisconsin Alumni Res Found | Primate embryonic stem cell culture |
| US8017395B2 (en) | 2004-12-17 | 2011-09-13 | Lifescan, Inc. | Seeding cells on porous supports |
| WO2006073966A1 (en) * | 2004-12-30 | 2006-07-13 | Stemlifeline, Inc. | Methods and systems relating to embryonic stem cell lines |
| US20060275899A1 (en) * | 2004-12-30 | 2006-12-07 | Stemlifeline, Inc. | Methods and compositions relating to embryonic stem cell lines |
| CN1298843C (en) * | 2005-02-07 | 2007-02-07 | 十堰市太和医院 | Human embryonic stem cells culture medium without dependent feeding cell |
| AU2006202209B2 (en) * | 2005-05-27 | 2011-04-14 | Lifescan, Inc. | Amniotic fluid derived cells |
| WO2006133052A2 (en) * | 2005-06-08 | 2006-12-14 | Centocor, Inc. | A cellular therapy for ocular degeneration |
| WO2007002086A2 (en) * | 2005-06-22 | 2007-01-04 | Geron Corporation | Suspension culture of human embryonic stem cells |
| WO2007016366A2 (en) * | 2005-07-29 | 2007-02-08 | Yale University | Defined culture conditions of human embryonic stem cells |
| KR100670616B1 (en) * | 2005-08-25 | 2007-01-17 | 주식회사 메디아나전자 | Artificial blstocyst for cultivating cells using epithelial cell or fibroblast, cultivating apparatus thereof |
| AU2006285467A1 (en) * | 2005-09-02 | 2007-03-08 | Agency For Science, Technology And Research | Method of deriving mesenchymal stem cells |
| WO2007044572A2 (en) * | 2005-10-06 | 2007-04-19 | University Of Massachusetts | Cell division marker |
| AU2006301549B2 (en) * | 2005-10-07 | 2013-02-14 | Cellartis Ab | A method for obtaining a xeno-free hBS cell line |
| ES2687233T3 (en) | 2005-10-27 | 2018-10-24 | Viacyte, Inc. | Endoderm of the dorsal and ventral proximal intestine expressing PDX-1 |
| US7413900B2 (en) * | 2005-10-31 | 2008-08-19 | President And Fellows Of Harvard College | Immortalized fibroblasts |
| US7695965B2 (en) | 2006-03-02 | 2010-04-13 | Cythera, Inc. | Methods of producing pancreatic hormones |
| US11254916B2 (en) | 2006-03-02 | 2022-02-22 | Viacyte, Inc. | Methods of making and using PDX1-positive pancreatic endoderm cells |
| SG10201405380QA (en) | 2006-03-02 | 2014-10-30 | Cythera Inc | Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production |
| US7989204B2 (en) | 2006-04-28 | 2011-08-02 | Viacyte, Inc. | Hepatocyte lineage cells |
| EP2021462B1 (en) | 2006-04-28 | 2019-01-09 | Lifescan, Inc. | Differentiation of human embryonic stem cells |
| US8741643B2 (en) | 2006-04-28 | 2014-06-03 | Lifescan, Inc. | Differentiation of pluripotent stem cells to definitive endoderm lineage |
| CN100465268C (en) * | 2006-05-17 | 2009-03-04 | 北京大学 | Culture method for human embryonic stem cell and special culture medium thereof |
| US7964402B2 (en) | 2006-05-25 | 2011-06-21 | Sanford-Burnham Medical Research Institute | Methods for culture and production of single cell populations of human embryonic stem cells |
| JP2009540826A (en) * | 2006-06-20 | 2009-11-26 | ジェンザイム・コーポレーション | Serum-free medium and its use for chondrocyte amplification |
| KR20090085019A (en) * | 2006-08-11 | 2009-08-06 | 주식회사 엠씨티티 | Culture medium for co-culturing of human stem cells and their feeder cells |
| US20100323442A1 (en) * | 2006-10-17 | 2010-12-23 | Emmanuel Edward Baetge | Modulation of the phosphatidylinositol-3-kinase pathway in the differentiation of human embryonic stem cells |
| AU2007321928A1 (en) | 2006-11-24 | 2008-05-29 | Regents Of The University Of Minnesota | Endodermal progenitor cells |
| US10829733B2 (en) * | 2007-01-04 | 2020-11-10 | Biolamina Ab | Composition and method for enabling proliferation of pluripotent human stem cells |
| US7883698B2 (en) * | 2007-01-17 | 2011-02-08 | Maria Michejda | Isolation and preservation of fetal hematopoietic and mesencymal system cells from non-controversial materials and/or tissues resulting from miscarriages and methods of therapeutic use |
| KR20090115142A (en) * | 2007-01-30 | 2009-11-04 | 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 | Early mesoderm cells, a stable population of mesendoderm cells that has utility for generation of endoderm and mesoderm lineages and multipotent migratory cells(mmc) |
| US7951593B2 (en) * | 2007-03-20 | 2011-05-31 | Universite Rene Descartes-Paris V | Culture medium for gingival fibroblasts |
| KR101732952B1 (en) | 2007-07-01 | 2017-05-08 | 라이프스캔, 인코포레이티드 | Single pluripotent stem cell culture |
| US9080145B2 (en) | 2007-07-01 | 2015-07-14 | Lifescan Corporation | Single pluripotent stem cell culture |
| CN101861386A (en) | 2007-07-18 | 2010-10-13 | 生命扫描有限公司 | The differentiation of human embryo stem cell |
| DK2185693T3 (en) | 2007-07-31 | 2019-09-23 | Lifescan Inc | DIFFERENTIZING HUMAN EMBRYONIC STEM CELLS |
| ES2665434T3 (en) | 2007-07-31 | 2018-04-25 | Lifescan, Inc. | Differentiation of pluripotent stem cells using human feeder cells |
| US7695963B2 (en) | 2007-09-24 | 2010-04-13 | Cythera, Inc. | Methods for increasing definitive endoderm production |
| CN107574142B (en) * | 2007-11-27 | 2021-07-06 | 生命扫描有限公司 | Differentiation of human embryonic stem cells |
| US20100087002A1 (en) * | 2008-02-21 | 2010-04-08 | Benjamin Fryer | Methods, Surface Modified Plates and Compositions for Cell Attachment, Cultivation and Detachment |
| CA2715878C (en) | 2008-02-21 | 2017-06-13 | Centocor Ortho Biotech Inc. | Methods, surface modified plates and compositions for cell attachment, cultivation and detachment |
| WO2009131568A1 (en) | 2008-04-21 | 2009-10-29 | Cythera, Inc. | Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells |
| US8338170B2 (en) | 2008-04-21 | 2012-12-25 | Viacyte, Inc. | Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells |
| US7939322B2 (en) | 2008-04-24 | 2011-05-10 | Centocor Ortho Biotech Inc. | Cells expressing pluripotency markers and expressing markers characteristic of the definitive endoderm |
| US8623648B2 (en) * | 2008-04-24 | 2014-01-07 | Janssen Biotech, Inc. | Treatment of pluripotent cells |
| EP3851520A1 (en) | 2008-04-30 | 2021-07-21 | SanBio, Inc. | Neural regenerating cells with alterations in dna methylation |
| US20090298178A1 (en) * | 2008-06-03 | 2009-12-03 | D Amour Kevin Allen | Growth factors for production of definitive endoderm |
| DK2297319T3 (en) | 2008-06-03 | 2015-10-19 | Viacyte Inc | GROWTH FACTORS FOR PREPARING DEFINITIVE ENDODERM |
| KR20180018839A (en) | 2008-06-30 | 2018-02-21 | 얀센 바이오테크 인코포레이티드 | Differentiation of pluripotent stem cells |
| WO2010002785A1 (en) * | 2008-06-30 | 2010-01-07 | Centocor Ortho Biotech Inc. | Differentiation of pluripotent stem cells |
| CA2731821A1 (en) | 2008-07-25 | 2010-01-28 | Stephen Dalton | Compositions for mesoderm derived isl1+ multipotent cells (imps), epicardial progenitor cells (epcs) and multipotent cxcr4+cd56+ cells (c56cs) and methods of use |
| US20110305672A1 (en) | 2008-07-25 | 2011-12-15 | University Of Georgia Research Foundation, Inc. | COMPOSITIONS FOR MESODERM DERIVED ISL1+ MULTIPOTENT CELLS (IMPs), EPICARDIAL PROGENITOR CELLS (EPCs) AND MULTIPOTENT CD56C CELLS (C56Cs) AND METHODS OF PRODUCING AND USING SAME |
| US20100028307A1 (en) * | 2008-07-31 | 2010-02-04 | O'neil John J | Pluripotent stem cell differentiation |
| JP2012507289A (en) | 2008-10-31 | 2012-03-29 | ヤンセン バイオテツク，インコーポレーテツド | Differentiation of human embryonic stem cells into the pancreatic endocrine system |
| US9234178B2 (en) | 2008-10-31 | 2016-01-12 | Janssen Biotech, Inc. | Differentiation of human pluripotent stem cells |
| CA2907326A1 (en) | 2008-11-04 | 2010-05-14 | Chad Green | Stem cell aggregate suspension compositions and methods for differentiation thereof |
| EP2356227B1 (en) | 2008-11-14 | 2018-03-28 | Viacyte, Inc. | Encapsulation of pancreatic cells derived from human pluripotent stem cells |
| MX356756B (en) | 2008-11-20 | 2018-06-11 | Centocor Ortho Biotech Inc | Pluripotent stem cell culture on micro-carriers. |
| EP2366022B1 (en) * | 2008-11-20 | 2016-04-27 | Janssen Biotech, Inc. | Methods and compositions for cell attachment and cultivation on planar substrates |
| US20100209399A1 (en) * | 2009-02-13 | 2010-08-19 | Celavie Biosciences, Llc | Brain-derived stem cells for repair of musculoskeletal system in vertebrate subjects |
| US8642334B2 (en) | 2009-02-17 | 2014-02-04 | Memorial Sloan Kettering Cancer Center | Methods of neural conversion of human embryonic stem cells |
| US9109245B2 (en) | 2009-04-22 | 2015-08-18 | Viacyte, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
| DK2421957T3 (en) | 2009-04-22 | 2021-01-25 | Viacyte Inc | CELL COMPOSITIONS DERIVED FROM DEDIFFERENTIATED PROGRAMMED CELLS |
| US8785185B2 (en) | 2009-07-20 | 2014-07-22 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
| JP5819825B2 (en) | 2009-07-20 | 2015-11-24 | ヤンセン バイオテツク，インコーポレーテツド | Differentiation of human embryonic stem cells |
| JP6219568B2 (en) | 2009-07-20 | 2017-10-25 | ヤンセン バイオテツク，インコーポレーテツド | Differentiation of human embryonic stem cells |
| WO2011017315A2 (en) | 2009-08-03 | 2011-02-10 | Recombinetics, Inc. | Methods and compositions for targeted gene modification |
| EP2494035B1 (en) * | 2009-10-29 | 2018-02-28 | Janssen Biotech, Inc. | Pluripotent stem cells |
| EP2501802A4 (en) | 2009-11-17 | 2013-08-21 | Advanced Cell Tech Inc | Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells |
| MX343786B (en) * | 2009-12-23 | 2016-11-22 | Janssen Biotech Inc | Differentiation of human embryonic stem cells. |
| RU2664864C1 (en) * | 2009-12-23 | 2018-08-23 | Янссен Байотек, Инк. | Ways to increase expression of ngn3 and nkx6.1 in pancreatic endocrine cells |
| JP6013196B2 (en) * | 2010-03-01 | 2016-10-25 | ヤンセン バイオテツク，インコーポレーテツド | Method for purifying cells derived from pluripotent stem cells |
| RU2587634C2 (en) | 2010-05-12 | 2016-06-20 | Янссен Байотек, Инк. | Differentiation of human embryo stem cells |
| WO2012009377A2 (en) | 2010-07-12 | 2012-01-19 | University Of Southern California | Biocompatible substrate for facilitating interconnections between stem cells and target tissues and methods for implanting same |
| SG10201506264QA (en) | 2010-08-12 | 2015-09-29 | Janssen Biotech Inc | Treatment of diabetes with pancreatic endocrine precursor cells |
| KR101851956B1 (en) | 2010-08-31 | 2018-04-25 | 얀센 바이오테크 인코포레이티드 | Differentiation of human embryonic stem cells |
| ES2659393T3 (en) | 2010-08-31 | 2018-03-15 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
| ES2585028T3 (en) | 2010-08-31 | 2016-10-03 | Janssen Biotech, Inc. | Differentiation of pluripotent stem cells |
| CA2814860C (en) | 2010-10-22 | 2020-08-25 | Biotime Inc. | Methods of modifying transcriptional regulatory networks in stem cells |
| JP6002675B2 (en) * | 2010-12-17 | 2016-10-05 | ビオラミナ アーベー | Cell culture media |
| EP2801377B1 (en) | 2011-03-04 | 2019-08-07 | The Regents of The University of California | Hydrogel comprising cells for local release of growth factors to mediate motor recovery after stroke |
| US8785190B2 (en) | 2011-04-06 | 2014-07-22 | Sanbio, Inc. | Methods and compositions for modulating peripheral immune function |
| US8877489B2 (en) | 2011-12-05 | 2014-11-04 | California Institute Of Technology | Ultrathin parylene-C semipermeable membranes for biomedical applications |
| US10478206B2 (en) | 2011-04-29 | 2019-11-19 | University Of Southern California | Instruments and methods for the implantation of cell-seeded substrates |
| WO2012170853A1 (en) | 2011-06-10 | 2012-12-13 | Wisconsin Alumni Research Foundation ("Warf") | Methods and devices for differentiating pluripotent stem cells into cells of the pancreatic lineage |
| WO2013010045A1 (en) | 2011-07-12 | 2013-01-17 | Biotime Inc. | Novel methods and formulations for orthopedic cell therapy |
| CA2854578C (en) | 2011-11-04 | 2023-01-03 | Memorial Sloan-Kettering Cancer Center | Midbrain dopamine (da) neurons for engraftment |
| US9248013B2 (en) | 2011-12-05 | 2016-02-02 | California Institute Of Technology | 3-Dimensional parylene scaffold cage |
| RU2705001C2 (en) | 2011-12-22 | 2019-11-01 | Янссен Байотек, Инк. | Differentiation of human embryonic stem cells into single-hormonal insulin-positive cells |
| CA2866590A1 (en) | 2012-03-07 | 2013-09-12 | Janssen Biotech, Inc. | Defined media for expansion and maintenance of pluripotent stem cells |
| KR20160027217A (en) | 2012-05-23 | 2016-03-09 | 에프. 호프만-라 로슈 아게 | Compositions and methods of obtaining and using endoderm and hepatocyte cells |
| JP6469003B2 (en) | 2012-06-08 | 2019-02-13 | ヤンセン バイオテツク，インコーポレーテツド | Differentiation of human embryonic stem cells into pancreatic endocrine cells |
| CN102732477B (en) * | 2012-06-15 | 2013-06-19 | 江苏瑞思坦生物科技有限公司 | Human adipose-derived stem cell serum-free basic medium |
| KR102055438B1 (en) | 2012-07-31 | 2019-12-19 | 에이지엑스 쎄라퓨틱스, 인크. | Hla g-modified cells and methods |
| AU2013237760A1 (en) | 2012-10-08 | 2014-04-24 | Biotime, Inc. | Differentiated progeny of clonal progenitor cell lines |
| AU2013248265B2 (en) | 2012-11-08 | 2018-11-01 | Viacyte, Inc. | Scalable primate pluripotent stem cell aggregate suspension culture and differentiation thereof |
| JP6557146B2 (en) | 2012-12-31 | 2019-08-07 | ヤンセン バイオテツク，インコーポレーテツド | Culture of human embryonic stem cells at the air-liquid interface for differentiation from pluripotent stem cells to pancreatic endocrine cells |
| EP2938723B1 (en) | 2012-12-31 | 2023-02-01 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells into pancreatic endocrine cells using hb9 regulators |
| US10370644B2 (en) | 2012-12-31 | 2019-08-06 | Janssen Biotech, Inc. | Method for making human pluripotent suspension cultures and cells derived therefrom |
| EP4039798A1 (en) | 2012-12-31 | 2022-08-10 | Janssen Biotech, Inc. | Suspension and clustering of human pluripotent cells |
| US8859286B2 (en) | 2013-03-14 | 2014-10-14 | Viacyte, Inc. | In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells |
| EP2989198A4 (en) | 2013-04-26 | 2016-10-26 | Sloan Kettering Inst Cancer | Cortical interneurons and other neuronal cells produced by the directed differentiation of pluripotent and multipotent cells |
| WO2014197421A1 (en) | 2013-06-05 | 2014-12-11 | Biotime, Inc. | Compositions and methods for induced tissue regeneration in mammalian species |
| JP2016527878A (en) | 2013-06-14 | 2016-09-15 | ザ ユニバーシティー オブ クイーンズランド | Renal progenitor cells |
| EP3071685A4 (en) | 2013-11-21 | 2017-07-05 | Memorial Sloan Kettering Cancer Center | Specification of functional cranial placode derivatives from human pluripotent stem cells |
| US11078462B2 (en) | 2014-02-18 | 2021-08-03 | ReCyte Therapeutics, Inc. | Perivascular stromal cells from primate pluripotent stem cells |
| CA2949056A1 (en) | 2014-05-16 | 2015-11-19 | Janssen Biotech, Inc. | Use of small molecules to enhance mafa expression in pancreatic endocrine cells |
| US10240127B2 (en) | 2014-07-03 | 2019-03-26 | ReCyte Therapeutics, Inc. | Exosomes from clonal progenitor cells |
| CN104357379B (en) * | 2014-09-30 | 2017-08-08 | 刘兴宇 | Stem cell media |
| EP3387112A4 (en) | 2015-12-07 | 2019-08-21 | BioTime, Inc. | Methods for the re-derivation of diverse pluripotent stem cell-derived brown fat cells |
| EP3423158B1 (en) | 2016-02-24 | 2023-11-15 | The Rockefeller University | Embryonic cell-based therapeutic candidate screening systems, models for huntington's disease and uses thereof |
| MA45479A (en) | 2016-04-14 | 2019-02-20 | Janssen Biotech Inc | DIFFERENTIATION OF PLURIPOTENT STEM CELLS IN ENDODERMAL CELLS OF MIDDLE INTESTINE |
| KR101877793B1 (en) * | 2016-07-15 | 2018-07-13 | 주식회사 엔바이오텍 | Serum-Free Medium Composition for Stem Cell Culture and Methods for Culturing Stem Cells Using the Same |
| AU2017335841A1 (en) | 2016-09-28 | 2019-04-04 | Organovo, Inc. | Use of engineered renal tissues in assays |
| CN106754652B (en) * | 2017-03-06 | 2019-04-02 | 广州润虹医药科技股份有限公司 | IPS cell differentiation at ectoderm progenitor cells serum-free induced medium and abductive approach |
| CN106754657B (en) * | 2017-03-28 | 2022-07-22 | 北京赛斯达生物技术有限公司 | Serum-free medium for monkey embryonic stem cells |
| US20210123016A1 (en) | 2018-05-02 | 2021-04-29 | Novartis Ag | Regulators of human pluripotent stem cells and uses thereof |
| CN114109294A (en) * | 2020-08-26 | 2022-03-01 | 中石化胜利石油工程有限公司管具技术服务中心 | Flashboard dismouting device and control system thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US670372A (en) * | 1898-01-13 | 1901-03-19 | William D Carpenter | Process of producing casein products. |
| US5612211A (en) * | 1990-06-08 | 1997-03-18 | New York University | Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors |
| US5750376A (en) * | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
| US5639046A (en) * | 1992-07-21 | 1997-06-17 | Fabio Perini S.P.A. | Machine and method for the formation of coreless logs of web material |
| US5453357A (en) | 1992-10-08 | 1995-09-26 | Vanderbilt University | Pluripotential embryonic stem cells and methods of making same |
| US5690926A (en) | 1992-10-08 | 1997-11-25 | Vanderbilt University | Pluripotential embryonic cells and methods of making same |
| US5405772A (en) | 1993-06-18 | 1995-04-11 | Amgen Inc. | Medium for long-term proliferation and development of cells |
| US5843780A (en) * | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| AU3392697A (en) | 1996-06-14 | 1998-01-07 | Regents Of The University Of California, The | (in vitro) derivation and culture of primate pluripotent stem cells and therapeutic uses thereof |
| JP2001508302A (en) | 1997-01-10 | 2001-06-26 | ライフ テクノロジーズ，インコーポレイテッド | Embryonic stem cell serum replacement |
| US6331406B1 (en) * | 1997-03-31 | 2001-12-18 | The John Hopkins University School Of Medicine | Human enbryonic germ cell and methods of use |
| GB9722370D0 (en) * | 1997-10-22 | 1997-12-17 | Ici Plc | Dye sheet cassette and printing apparatus |
| US6800480B1 (en) | 1997-10-23 | 2004-10-05 | Geron Corporation | Methods and materials for the growth of primate-derived primordial stem cells in feeder-free culture |
| DE19756864C5 (en) | 1997-12-19 | 2014-07-10 | Oliver Brüstle | Neural precursor cells, methods for their production and their use for the therapy of neural defects |
| US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
| US7410798B2 (en) * | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
| DE60026512D1 (en) | 1999-05-07 | 2006-05-04 | Univ Utah Res Found | ON A CELL LINE RESTRICTED CELLS FROM THE NEURAL TUBE OF MOUSE AND EMBRYONAL STEM CELLS OF MOUSE |
| IL129966A (en) * | 1999-05-14 | 2009-12-24 | Technion Res & Dev Foundation | ISOLATED HUMAN EMBRYOID BODIES (hEB) DERIVED FROM HUMAN EMBRYONIC STEM CELLS |
| US6750581B2 (en) * | 2002-01-24 | 2004-06-15 | Visteon Global Technologies, Inc. | Automotive alternator stator assembly with rectangular continuous wire |
-
2000
- 2000-03-09 US US09/522,030 patent/US7005252B1/en not_active Expired - Lifetime
-
2001
- 2001-03-02 JP JP2001565854A patent/JP5717311B2/en not_active Expired - Lifetime
- 2001-03-02 IL IL15127001A patent/IL151270A0/en unknown
- 2001-03-02 EP EP01913296.8A patent/EP1261691B1/en not_active Expired - Lifetime
- 2001-03-02 NZ NZ520701A patent/NZ520701A/en not_active IP Right Cessation
- 2001-03-02 MX MXPA02008698A patent/MXPA02008698A/en active IP Right Grant
- 2001-03-02 AU AU2001241973A patent/AU2001241973B2/en not_active Expired
- 2001-03-02 BR BR0108507-7A patent/BR0108507A/en not_active Application Discontinuation
- 2001-03-02 CN CNB018062350A patent/CN100372928C/en not_active Expired - Lifetime
- 2001-03-02 CA CA2402299A patent/CA2402299C/en not_active Expired - Lifetime
- 2001-03-02 WO PCT/US2001/006912 patent/WO2001066697A2/en active IP Right Grant
- 2001-03-02 KR KR1020027011681A patent/KR100795760B1/en active IP Right Grant
- 2001-03-02 AU AU4197301A patent/AU4197301A/en active Pending
-
2002
- 2002-08-14 IL IL151270A patent/IL151270A/en unknown
- 2002-08-20 IS IS6515A patent/IS6515A/en unknown
- 2002-09-03 NO NO20024200A patent/NO335780B1/en not_active IP Right Cessation
-
2003
- 2003-05-06 US US10/430,497 patent/US7217569B2/en not_active Expired - Lifetime
- 2003-08-22 HK HK03106031A patent/HK1053616A1/en unknown
-
2004
- 2004-09-28 US US10/952,096 patent/US20050148070A1/en not_active Abandoned
-
2005
- 2005-10-25 US US11/257,704 patent/US20060040384A1/en not_active Abandoned
-
2011
- 2011-07-27 JP JP2011164419A patent/JP5839666B2/en not_active Expired - Lifetime
- 2011-07-27 JP JP2011164743A patent/JP2011234735A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL151270A0 (en) | 2003-04-10 |
| WO2001066697A3 (en) | 2002-03-07 |
| CN100372928C (en) | 2008-03-05 |
| US7217569B2 (en) | 2007-05-15 |
| IS6515A (en) | 2002-08-20 |
| NO20024200L (en) | 2002-09-03 |
| MXPA02008698A (en) | 2003-04-14 |
| HK1053616A1 (en) | 2003-10-31 |
| IL151270A (en) | 2008-07-08 |
| NO335780B1 (en) | 2015-02-16 |
| AU4197301A (en) | 2001-09-17 |
| US20060040384A1 (en) | 2006-02-23 |
| CA2402299A1 (en) | 2001-09-13 |
| US7005252B1 (en) | 2006-02-28 |
| NO20024200D0 (en) | 2002-09-03 |
| JP2003525625A (en) | 2003-09-02 |
| JP5839666B2 (en) | 2016-01-06 |
| NZ520701A (en) | 2004-03-26 |
| EP1261691B1 (en) | 2013-07-31 |
| JP5717311B2 (en) | 2015-05-13 |
| CN1416345A (en) | 2003-05-07 |
| AU2001241973B2 (en) | 2006-11-09 |
| JP2011234735A (en) | 2011-11-24 |
| BR0108507A (en) | 2002-12-17 |
| EP1261691A2 (en) | 2002-12-04 |
| US20030190748A1 (en) | 2003-10-09 |
| JP2012005489A (en) | 2012-01-12 |
| US20050148070A1 (en) | 2005-07-07 |
| WO2001066697A2 (en) | 2001-09-13 |
| KR100795760B1 (en) | 2008-01-21 |
| KR20030032926A (en) | 2003-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2402299C (en) | Serum free cultivation of primate embryonic stem cells | |
| AU2001241973A1 (en) | Serum free cultivation of primate embryonic stem cells | |
| AU2005289597B2 (en) | Cultivation of primate embryonic stem cells | |
| JP5227318B2 (en) | Cell growth medium | |
| EP1749091B1 (en) | Feeder independent extended culture of embryonic stem cells | |
| US20120178160A1 (en) | Cultivation Of Primate Embryonic Stem Cells | |
| AU2007200575B2 (en) | Serum free cultivation of primate embryonic stem cells | |
| JP6314193B2 (en) | Culture of primate embryonic stem cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20210302 |